Relationship between Apolipoprotein E polymorphism and nephropathy in type-2 diabetic patients.

Area of Science:

• Nephrology
• Genetics
• Endocrinology

Background:

• Diabetic nephropathy affects 20-40% of type-2 diabetic patients (DM2).
• Apolipoprotein E (Apo E) genetic polymorphism is a potential risk factor for diabetic nephropathy.
• Understanding genetic predispositions is crucial for managing diabetic kidney disease.

Purpose of the Study:

• To investigate the association between Apolipoprotein E (Apo E) gene polymorphism and the presence of nephropathy in type-2 diabetic patients.
• To evaluate the role of different Apo E genotypes in the development and progression of diabetic kidney complications.

Main Methods:

• Study included 85 type-2 diabetic patients with over 10 years of disease duration.
• Patients were categorized into groups with (n=56) and without (n=29) kidney complications.
• Apolipoprotein E (Apo E) genotyping was performed using restriction fragment-length polymorphism analysis, alongside biochemical and clinical assessments.

Main Results:

• The nephropathy group exhibited significant differences in BMI, blood pressure, glycemic control (HbA1c), and lipid profiles (cholesterol, HDL, LDL), and creatinine levels compared to controls.
• The e4 allelic frequency was significantly lower (8%) in the nephropathy group versus the control group (25.9%).
• Patients without nephropathy showed a higher frequency of the e4 allele, while the e3 allele and E3/3 genotype were more prevalent in the nephropathy group.

Conclusions:

• The Apolipoprotein E (Apo E) e4 allele may confer a protective effect against the development and progression of diabetic nephropathy in type-2 diabetes.
• Findings suggest that Apo E genotype could be a significant factor influencing kidney complication risk in DM2 patients.
• Further research is warranted to elucidate the mechanisms behind the potential protective role of the e4 allele.